News

Neuraxial anesthesia, a focus of this study, refers to the administration of local anesthetics and analgesia to targeted locations in the spinal…

The commercialization and licensing agreement between the two companies went into effect on May 6th. May 7, 2021 uniQure recently announced that…

Kevin Mills, PhD has joined the National Hemophilia Foundation as chief scientific officer. A graduate of University of Colorado Boulder, MIT, and…

Late last year the FDA put a clinical hold on the program in response to a single trial participant who was diagnosed…

by: Michael Hickey Caregivers devote themselves to the well-being of others, but to be their best they need to practice self-care. Being…

Biochemist Gordon Vehar, PhD, vice president of external innovation at BioMarin Pharmaceutical Inc., has been at the forefront of a scientific revolution….

Hemophilia Treatment Centers (HTCs) across the United States are participating in the 2021 National HTC Patient Satisfaction Survey! If you, or someone…

We have been limited in our ability to meet face-to-face over the last year, but we want to continue to stay connected…

You can enroll in health plans due to the COVID-19 emergency through August 15, or anytime if you have certain life changes…

Whereas; since its designation by the World Federation of Hemophilia in 1989, World Hemophilia Day has been celebrated on April 17 as…

Early studies have indicated that women who are pregnant or breastfeeding who have received a COVID-19 vaccination can pass antibodies along to…

There has been much positive news around the US vaccine efforts: about 207.9 million doses of the vaccine have been administered, 62.4 million…

You have been reaching out to us with your questions and concerns about the COVID-19 vaccines and we are grateful that you…

The Platelet Disorder Support Association recently recorded a patient education webinar on the new COVID-19 vaccines and immune thrombocytopenic purpura (ITP) As…

The focus of the HOPE-B trial is etranacogene dezaparvovec, uniQure’s investigational gene therapy candidate for individuals with severe and moderately severe hemophilia…

The new law lowers costs and opens up new options to get health insurance coverage. The American Rescue Plan (ARP), signed into…

In the age of high deductibles and patient out-of-pocket expenditures, more and more people depend on copay assistance to afford their life-saving…

Phone2Action is a new software system that allows GLHF to connect with you regarding our state advocacy work. It gives us the opportunity to share…

Spark Therapeutics announced preliminary data from part one of their ongoing phase 1/2 open-label, non-randomized, dose-finding study of SPK-8016, the company’s investigational…

Source: Joint statement from the European Hemophilia Consortium, the World Federation of Hemophilia, and the National Hemophilia Foundation Fitusiran update following EAHAD…

This year, in celebration of World Hemophilia Day, Saturday, April 17, we’re challenging the bleeding disorders community to a friendly game of…

Scientists – including Dr. Fauci – are estimating that around 90% of the US population would need to be either recovered from…

CDC COVID Data Tracker: To date, there have been 27,879,604 cases reported in the US resulting in nearly 500,000 deaths of Americans!…

by: Dr. Leonard Valentino, Chief Executive Officer, National Hemophilia Foundation So, where are we with vaccines for COVID-19? Well, let’s first start…